Evolus (NASDAQ:EOLS) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Evolus (NASDAQ:EOLS) in a report released on Wednesday,Benzinga reports. They currently have a $22.00 price objective on the stock.

Other equities analysts have also recently issued research reports about the company. Barclays boosted their price objective on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of Evolus in a research note on Wednesday.

Evolus Price Performance

NASDAQ EOLS opened at $14.17 on Wednesday. Evolus has a twelve month low of $9.25 and a twelve month high of $17.82. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The stock has a market capitalization of $897.26 million, a PE ratio of -15.57 and a beta of 1.33. The stock has a 50-day simple moving average of $12.79 and a 200 day simple moving average of $14.08.

Hedge Funds Weigh In On Evolus

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. KBC Group NV bought a new position in Evolus during the fourth quarter valued at about $49,000. IFP Advisors Inc grew its stake in shares of Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after purchasing an additional 4,709 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of Evolus in the 4th quarter valued at approximately $106,000. Rafferty Asset Management LLC bought a new stake in shares of Evolus in the 4th quarter valued at approximately $115,000. Finally, Quantbot Technologies LP bought a new stake in shares of Evolus in the 4th quarter valued at approximately $118,000. 90.69% of the stock is currently owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.